Condition: Myocardial Infarction · Reperfusion Injury · AMI · Sponsor: Nyrada Pty Ltd
This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study is to determine whether a medicine called Xolatryp is safe and effective in improving cardiac outcomes. One dose of Xolatryp will be tested in this study. Participants are put into two groups randomly, which means by chance. One group receives a single 6-hour continuous intravenous infusion of Xolatryp and one group receives placebo. Participants are in the study for about 30 days. Placebo infusion looks like Xolatryp but do not contain any medicine. Participants are followed up via telephone and there is one visit to the study site on day 30. Heart health is assessed based on the analysis of blood samples, which are collected at the study site, via electrocardiogram (ECG), echocardiogram and cardiac magnetic resonance (CMR) imaging. At the end of the study, the results are compared between the two groups. During the study, the doctors also regularly check the general health of the participants.
This description comes directly from the study's public registry record.
Alexandra Suchowerska Director, Clinical Operations and Regulatory Affairs, PhD · +61 294-983-390 · Protect-MI@Nyrada.com
Always discuss trial participation with your own doctor first.
| Nepean Hospital | Kingswood, New South Wales, Australia | Recruiting |
| Liverpool Hospital | Liverpool, New South Wales, Australia | Not Yet Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Not Yet Recruiting |
| Northern Health | Epping, Victoria, Australia | Not Yet Recruiting |
| Sunshine Hospital | Saint Albans, Victoria, Australia | Not Yet Recruiting |
| Sir Charles Gairdner Hospital | Nedlands, Western Australia, Australia | Recruiting |
| Royal Perth Hospital | Perth, Western Australia, Australia | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07362446